Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The ...
TipRanks on MSN
Lexicon announces publication of preclinical data on ACSL5
Lexicon Pharmaceuticals (LXRX) announced the publication of preclinical data validating Acyl-CoA Synthetase 5 as a target for obesity and chronic ...
TipRanks on MSN
Mixed options sentiment in Novo Nordisk with shares up 4.0%
Mixed options sentiment in Novo Nordisk (NVO), with shares up $1.85, or 4.0%, near $48.22. Options volume roughly in line with average with 31k ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback